A Phase II Study of CMP-001 and Nivolumab in People with Advanced Melanoma that Persists Despite Immunotherapy

Source: Memorial Sloan Kettering Cancer Center

Full Title

A Multicenter, Open Label, Phase 2 Study of Intratumoral CMP-001 in Combination with Intravenous Nivolumab in Subjects with Refractory Unresectable or Metastatic Melanoma

Purpose

The purpose of this study is to assess the safety and effectiveness of combining the investigational drug CMP-001 with the immunotherapy drug nivolumab in people with inoperable or metastatic melanoma that continues to grow despite standard immunotherapy. It is hoped that CMP-001 may stimulate fighter cells (T cells) in the immune system to attack the cancer.

Combining CMP-001 with nivolumab may make nivolumab more effective in boosting the ability of the immune system to shrink or halt the growth of tumors. CMP-001 is injected directly into a tumor and nivolumab is given intravenously (by vein).